drugs.com monograph bevacizumab licence EU Avastin licence US Bevacizumab pregnancy US C legal .... 149 kDa Bevacizumab trade name Avastin , Genentech Hoffmann La Roche Roche is a drug that slows ..., lung, breast outside the USA , glioblastoma USA only , kidney and ovarian. Bevacizumab is a humanized ... Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer year ... of diseases, especially in cancer . Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. Citation needed date August 2010 Bevacizumab was approved by the Food ..., and glioblastoma multiforme of the brain. At one point bevacizumab was approved for breast cancer by the FDA ... bevacizumab provisional approval for metastatic breast cancer, subject to further studies. The FDA ... therapy , clinical studies are underway in breast cancer and lung cancer. Background Bevacizumab ... dependant on angiogenesis it was expected that Bevacizumab can stop or delay growth of tumors. Indications Colorectal cancer Bevacizumab was approved by the FDA in February 2004 for use in metastatic ... was based on E3200 trial addition of bevacizumab to oxaliplatin 5 FU leucovorin FOLFOX4 therapy. In adjuvant ... date December 2010 Lung cancer In 2006, the FDA approved bevacizumab for use in first line advanced ... , which demonstrated a 2 month improvement in overall survival in patients treated with bevacizumab ... survival benefit with bevacizumab for patients with adenocarcinoma Sandler, et al. JTO 2010 adenocarcinoma ... in patients treated with bevacizumab however, this may be due to the more limited use of bevacizumab as maintenance treatment in AVAiL versus E4599 this differential effect is also apparent in the European vs US trials of bevacizumab in colorectal cancer Tyagi and Grothey, Clin Colorectal ... bevacizumab before disease progression. Stated another way, the survival benefits achieved with bevacizumab ... progression or treatment limiting side effects. Another large European based clinical trial with bevacizumab ... more details
antibody fragment Fragment antigen binding Fab derived from the same parent mouse antibody as bevacizumab ..., compared to bevacizumab, which can be prepared for macular degeneration treatment in doses that cost ... after dividing bevacizumab into smaller doses. ref name WSJ cite news url http online.wsj.com ... 10.1136 bmj.c2459 title Bevacizumab for neovascular age related macular degeneration ABC Trial multicentre ... ranibizumab rather than their less expensive bevacizumab. This may have been in anticipation of the results ... by the National Eye Institute, and compared the relative safety and efficacy of ranibizumab and bevacizumab in treating AMD. Some retina specialists consider the tactic bribery. In 2008, bevacizumab ... date November 3, 2010 ref A small study showed no superior effect of ranibizumab versus bevacizumab in direct comparison. ref cite journal doi 10.1038 eye.2010.147 title Bevacizumab vs ranibizumab ... doi 10.1056 NEJMoa1102673 title Ranibizumab and Bevacizumab for Neovascular Age Related Macular Degeneration ... more details
evidence suggests that treatment with one such drug, Bevacizumab , may be effective in treating ... and A. M. Evens. An open label multicenter phase II study of bevacizumab for the treatment of angiosarcoma ... Cancer Center, Houston, TX ref Investigation of bevacizumab in combination with other chemotherapy ... more details
This is a list of specific Wiktionary pharmacological agent pharmacologic agents that are known to be of use in the treatment of cancer , otherwise known as Wiktionary chemotherapeutic agent chemotherapeutic agents . This list is organized by type of agent, though the subsections are not necessarily definitive and are subject to revision. Each drug is listed once at present , though it might fall in more than one subsection. A full alphabetical listing is included after the categorical listing. Expand list date August 2008 Alkylating agents Cyclophosphamide Mechlorethamine Chlorambucil Melphalan Anthracyclines article on anthracycline s Daunorubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone Valrubicin Cytoskeletal disruptors Taxanes Paclitaxel Docetaxel Epothilones article on epothilone s Histone Deacetylase Inhibitors Vorinostat Romidepsin Inhibitors of Topoisomerase II Etoposide Teniposide Tafluposide Kinase Inhibitors Bortezomib Erlotinib Gefitinib Imatinib Vismodegib Monoclonal Antibodies Bevacizumab Cetuximab Ipilimumab Ofatumumab Ocrelizumab Panitumab Rituximab Vemurafenib Nucleotide analogs and precursor analogs Azacitidine Azathioprine Capecitabine Cytarabine Doxifluridine Fluorouracil Gemcitabine Hydroxyurea Mercaptopurine Methotrexate Tioguanine formerly Thioguanine Peptide antibiotics Bleomycin Actinomycin Platinum based agents Carboplatin Cisplatin Oxaliplatin Retinoids Tretinoin Alitretinoin Bexarotene Vinca alkaloids and derivatives Vinblastine Vincristine Vindesine Vinorelbine Full alphabetical listing Actinomycin All trans retinoic acid Azacitidine Azathioprine Bleomycin Bortezomib Carboplatin Capecitabine Cisplatin Chlorambucil Cyclophosphamide Cytarabine Daunorubicin Docetaxel Doxifluridine Doxorubicin Epirubicin Epothilone Etoposide Fluorouracil Gemcitabine Hydroxyurea Idarubicin Imatinib Mechlorethamine Mercaptopurine Methotrexate Mitoxantrone Oxaliplatin Paclitaxel Pemetrexed Teniposide Tioguanine Valrubicin Vinblastine Vincristine Vindesin ... more details
refimprove date January 2009 File Laura Perin, Napoleone Ferrara, and Matteo Garbelotto.jpg thumb Laura Perin , Napoleone Ferrara, and Matteo Garbelotto . Napoleone Ferrara , M.D. , Ph.D. is an Italian American molecular biologist and is currently a Genentech Fellow in tumor biology and angiogenesis. He is credited with identifying the human Vascular endothelial growth factor VEGF gene and describing its angiogenesis proangiogenic properties, which formed the basis for the development of Genentech s bevacizumab and Lucentis monoclonal antibody treatments. For his VEGF discovery, he won a Lasker Award in 2010. ref cite web url http www.laskerfoundation.org awards 2010 c description.htm title 2010 Winners Lasker DeBakey Clinical Medical Research Award author Strauss, Evelyn publisher The Lasker Foundation accessdate 2010 11 11 ref Education Dr. Ferrara received his medical degree from the Faculty of Medicine and Surgery at the University of Catania , Italy , in 1981 , and joined Genentech in 1988 . ref http www.sciencedirect.com science? ob ArticleURL& udi B6T64 4FYG6N7 5& user 4429& rdoc 1& fmt & orig search& sort d&view c& acct C000059602& version 1& urlVersion 0& userid 4429&md5 0c53e7083cf75f478bba859312458ba4 Napoleone Ferrara discusses Avastin and the future of anti angiogenesis therapy , ScienceDirect. ref References reflist Persondata Metadata see Wikipedia Persondata . NAME Ferrara, Napoleone ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Ferrara, Napoleone Category Year of birth missing living people Category Living people Category Italian scientists Category Molecular biologists italy biologist stub de Napoleone Ferrara ... more details
. The first anti VEGF drug, a monoclonal antibody named bevacizumab , was approved in 2004. Approximately 10 15 of patients benefit from bevacizumab therapy however, biomarkers for bevacizumab efficacy ... such as bevacizumab Avastin , antibody derivatives such as ranibizumab Lucentis , or orally available ... Ranibizumab , a monoclonal antibody fragment Fab derived from bevacizumab , has been developed ... ophthalmologists have turned to bevacizumab as the alternative intravitreal agent in the treatment of wet ... Journal of Ophthalmology that, unless ranibizumab is 2.5 times more effective the bevacizumab ... first5 A. title Ranibizumab Lucentis versus bevacizumab Avastin modelling cost effectiveness journal ... doi 10.1136 bjo.2007.116616 ref Off label use of intravitreal bevacizumab has become a widespread treatment ... Which? date June 2011 suggest that bevacizumab is effective in increasing visual acuity with low ... Institutes of Health NIH announced that it would fund a comparative study trial of ranibizumab and bevacizumab ... more details
?view long&pmid 16051960 ref The combination of bevacizumab and ABT 510 has been shown in a Clinical ... A, Howard L, Evans D, Li H, Hurwitz H title A phase I study of bevacizumab BV plus ABT 510 in patients ... more details
poor outcomes. Intravitreal injection of bevacizumab Avastin has been reported as a supportive measure ..., Tawansy KA, Raghuram A, Narendran K. title Intravitreal bevacizumab Avastin for post laser anterior ... clinical trial comparing bevacizumab with conventional laser therapy, intravitreal bevacizumab ... more details
inline citations date November 2011 Infobox Disease Name PAGENAME Image Caption DiseasesDB ICD10 ICD10 J 34 8 j 30 ICD9 ICD9 478.1 ICDO OMIM MedlinePlus eMedicineSubj eMedicineTopic MeshID A nasal septum perforation is a medical condition in which the nasal septum , the cartilage cartilaginous membrane dividing the nostrils , develops a hole or fissure. This may be brought on directly, as in the case of nasal body piercing piercing s, or indirectly, as by long term topical drug use like cocaine or decongestant nasal spray s, chronic nosebleed epistaxis , aggressive digital nasal cleaning nose picking and as a complication of nasal surgery like septoplasty or rhinoplasty . Much less common causes for perforated nasal septums include rare granulomatous inflammatory conditions like Wegener s granulomatosis . It has been reported as a side effect of anti angiogenesis drugs like bevacizumab . Symptoms A perforated septum can vary in size and location, and is usually found deep inside the nose. It may be asymptomatic, or cause a variety of symptoms. Small perforations can cause a whistling noise when breathing. Larger perforations usually have more severe symptoms. These can be a combination of crusting, blood discharge, difficulty breathing, nasal pressure and discomfort. The closer the perforation is to the nostrils, the more likely it is to cause symptoms. Treatment The majority of septal perforations can be managed without surgery. The hole will never close but if the open, raw trailing edge of the perforation can heal, the vast majority of symptoms resolve. The open irritated and raw surface must be continuously covered with a cream using a cotton applicator. This will prevent this area from drying out, cracking, bleeding, forming a scab and crusting up. A few months of successful application will allow the ulcerated edge to heal and reduces or resolves symptoms. In a small percentage of patients surgery is necessary to alleviate symptoms. There are several different ... more details
Infobox Disease Name Rubeosis iridis Image Caption DiseasesDB 11743 ICD10 ICD10 H 21 1 h 15 ICD9 ICD9 364.42 ICDO OMIM MedlinePlus eMedicineSubj eMedicineTopic MeshID Rubeosis iridis is a medical condition of the Iris anatomy iris of the eye in which new abnormal blood vessel s i.e. neovascularization are found on the surface of the iris. ref DorlandsDict seven 000093827 rubeosis iridis ref Pathophysiology It is usually associated with disease processes in the retina , which involve the retina becoming starved of oxygen ischaemic . The ischemic retina releases a variety of factors, the most important of which is VEGF. These factors stimulate the formation of new blood vessels angiogenesis . Unfortunately, these new vessels do not have the same characteristics as the blood vessels originally formed in the eye. In addition, new blood vessels can form in areas that do not have them. Specifically, new blood vessels can be observed on the iris. In addition to the blood vessels in the iris, they can grow into the angle of the eye. These blood vessels then block fluid leaving the eye and result in an increase in intraocular pressure. This is called neovascular glaucoma . Treatment If caught early, the neovascularization can be reversed with prompt pan retinal photocoagulation PRP , or injection of anti VEGF medications with subsequent PRP. The injection blocks the direct effect of VEGF and acts more quickly but will wear off in about 6 weeks. ref Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab Avastin injection. Retina. 2006 Mar 26 3 354 6. PMID 16508439. ref PRP has a slower onset of action but can last permanently. Once the neovascularization has been longstanding, the new vessels recruit fibrous tissue, and as this forms and contracts, the angle can be permanently damaged, and will not respond to treatment. If this occurs, then surgical intervention is required to reduce the pressure such as a glaucoma drainage implant C ... more details
General Hospital used the cancer drug Bevacizumab commercial name Avastin to treat 10 patients with neurofibromatosis ... patients treated with bevacizumab, tumours shrank in 9 of them, with the median best response ... with tumour shrinkage. Bevacizumab works by cutting the blood supply to the tumours and thus depriving ... neuro oncology.oxfordjournals.org cgi content full 12 1 14 ref Overall the researchers believed that bevacizumab ... before the full effects of bevacizumab can be established in NF2 patients. Management of Hearing Loss ... more details
Infobox non profit name The Breast Cancer Research Foundation image type founded date 1993 tax id registration id founder Evelyn H. Lauder location New York, NY coordinates origins key people Myra J. Biblowit, President area served product mission focus Breast Cancer Research method revenue endowment num volunteers num employees num members subsid opponents owner non profit slogan Prevention and A Cure in our Lifetime former name homepage http www.bcrfcure.org www.bcrfcure.org dissolved footnotes The Breast Cancer Research Foundation BCRF is an independent, not for profit organization which has raised USD 350 million to support clinical and translational research at medical institutions worldwide. BCRF currently funds 186 scientists across the United States, Canada, Latin America, Europe, the Middle East, Australia, and Asia. ref cite web url http www.bcrfcure.org action grantees.html title BCRF Grantees publisher The Breast Cancer Research Foundation ref The BCRF s director of research is Larry Norton , MD, of Memorial Sloan Kettering Cancer Center . BCRF has funded basic research on genetic susceptibility to breast cancer, breast cancer stem cells, trastuzumab Herceptin , anti angiogenesis treatment with bevacizumab Avastin , MRI imaging, aromatase inhibitors , tamoxifen and also clinical trials of new treatments with the Translational Breast Cancer Research Consortium . ref http www.bcrfcure.org about impact.html our impact The Breast Cancer Research Foundation What We ve Accomplished ref BCRF was founded in 1993 by Evelyn Lauder , Senior Corporate Vice President of The Estee Lauder Companies . Lauder s first foray into breast cancer awareness was through an initiative by herself and Alexandra Penney , former editor of Self magazine SELF magazine , to make the pink ribbon an international symbol of breast cancer awareness. ref cite web url http www.bcacampaign.com us about look.shtml title Breast Cancer Awareness Campaign publisher The Est e Lauder Companies Inc ... more details
Preferential hyperacuity perimetry is a psychophysical test used to identify and quantify visual abnormalities such as metamorphopsia and scotoma. Background Vision abnormalities such as metamorphopsia distortions and scotoma are symptoms of retinal diseases such as Macular degeneration . In advanced stages of the disease, photoreceptor cell s may be irreversibly damaged. Hence,if not treated Macular degeneration may lead to blindness. Awareness to early changes in vision, especially in high risk patients, leads to early treatment such as intravitreal injection of anti VEGF factors, e.g. bevacizumab or ranibizumab and prevents loss of vision. ref cite journal author Loewenstein A. title The significance of early detection of age related macular degeneration Richard & Hinda Rosenthal Foundation lecture. journal Retina. date September 2007 volume 27 issue 7 pages 873 878 pmid 17891011 ref Because of complex brain mechanisms such as Filling in , patients with small and peripheral defects in their vision are often unaware of such changes until late stages in the disease. ref cite journal author Achard OD, Safran AB, Duret FC, Ragama E. title Role of the completion phenomenon in the evaluation of Amsler grid results journal Am J Ophthalmol. date September 1995 volume 20 issue 3 pages 322 329 pmid 7661204 ref Another problem is that minute visual aberrations can be normal and therefore should be distinguished from genuine visual abnormalities. Preferential hyperacuity perimetry PHP is a technology that bypasses Filling in and quantifies the extent of visual abnormalities. ref cite journal author Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schahat AP, Bressler NM, Bressler SB, Conney MJ, Alster Y, Rafaeli O, Malach R. title Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age related macular degeneration . journal Retina. date April May 2005 volume 25 issue 3 pages 296 303 pmid 1 ... more details
Effectiveness and safety of bevacizumab for unresectable non small cell lung cancer a meta analysis ... 10.2165 11532260 000000000 00000 url ref Bevacizumab Avastin ref name Avastin http www.avastin.com avastin ... Bevacizumab may improve some measures of survival in both SCLC ref name HornDahlberg cite journal author ... of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive Stage Small Cell .... Citation needed date December 2010 Bevacizumab is contraindicated in squamous cell carcinoma and its ... more details
lymphocytic leukemia Bevacizumab Avastin 2004 humanized vascular endothelial growth factor colorectal ... has failed url journal J Clin Oncol volume 20 issue 1 pages 205 213 pmid 11773171 ref BevacizumabBevacizumab ... in tumor angiogenesis . Bevacizumab is indicated for colon cancer but has been applied to numerous other cancers in small scale studies, especially renal cell carcinoma . Results obtained showed that bevacizumab ... last7 Berlin first7 J last8 Baron first8 A last9 Griffing first9 S title Bevacizumab plus irinotecan ... more details
the drug bevacizumab brand name Avastin , a kind of humanized mouse monoclonal antibody against vascular ..., bevacizumab is an anti angiogenesis factor. Lowering the concentration of VEGF results in reduced ... bevacizumab Cancer binds vascular endothelial growth factor VEGF itraconazole Cancer inhibits ... more details
of this treatment modality. Recently, intravitreal injections of anti VEGF agents, namely bevacizumab ... reported patient with IJFT I, a single intravitreal bevacizumab injection resulted in a marked ... removal of CNV, photodynamic therapy with verteporfin and treatment with anti VEGF drugs such as bevacizumab ... more details
about side effects in the context of medicine side effects in the context of computer science Side effect computer science other uses In medicine , a side effect is an effect, whether therapeutic or adverse, that is secondary to the one intended although the term is predominantly employed to describe adverse effect s, it can also apply to beneficial, but unintended, consequences of the use of a drug . Occasionally, drugs are prescribed or procedures performed specifically for their side effects in that case, said side effect ceases to be a side effect, and is now an intended effect. For instance, X ray s were historically and are currently used as an imaging technique the discovery of their oncolytic capability led to their employ in radiotherapy ablation of malignancy malignant tumour s . Use of drugs for unapproved indications that is, for their side effects is termed off label use . For instance, opioids, which are approved as palliative care palliative treatment for pain , may also be used for their euphoriant properties as anxiolytics or antidepressants , whether medically or recreational drug use recreationally . Off label use of drugs, although similar in meaning to side effects, is not to be confused with them side effects describe the mechanism of action that a drug used off label takes, whereas off label use implies the desired consequences of using a drug for its side effects. Off label use of drugs is legal the manner in which prescription medication is to be used is solely at the discretion of the physician prescriber . However, the marketing of drugs towards unapproved indications is illegal in fact, several pharmaceutical development firms have been fined for unapproved promotion of their products. Examples of therapeutic side effects Bevacizumab Avastin has been used against wet age related macular degeneration , as well as macular edema from diseases such as diabetic retinopathy and central retinal vein occlusion . ref cite news url http www.guardia ... more details
Encyclopedia
top
